Global Toxoid Vaccines

Toxoid Vaccines Comprehensive Study by Type (Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, Pertussis (DTaP), Diphtheria and Tetanus (DT)), Forms (Quadrivalent, Pentavalent, Hexavalent), End-users (Hospitals And Clinics, Government Organizations, Research, Others) Players and Region - Global Market Outlook to 2026

Toxoid Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Toxoid Vaccines Market?

Toxoid vaccine uses a toxin (harmful product) made by the germ that causes a disease. These vaccines create immunity to the parts of the germ that cause disease instead of the germ itself. These vaccines generally used to protect against diseases such as Diptheria and Tetanus. These vaccines are safe because they cannot cause the disease they prevent and there is no possibility of reversion to virulence.

The market study is being classified by Type (Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, Pertussis (DTaP) and Diphtheria and Tetanus (DT)) and major geographies with country level break-up.

GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), AstraZeneca plc (United Kingdom), Bharat Biotech International Limited (India), Shenzhen Kangtai Biological Products (China), Bausch Health Companies Inc. (Canada) and Emergent BioSolutions Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Astellas Pharma Inc. (Japan) and Panacea Biotec (India).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Toxoid Vaccines market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Toxoid Vaccines market by Type, Application and Region.

On the basis of geography, the market of Toxoid Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Disease Caused by Microorganism such as Bacterial Infection
  • Increased Number of Diagnostic Centres
  • Increasing Healthcare Expenditure Across Emerging Markets

Market Trend
  • Increased Research and Development Activities

Restraints
  • Allergic Reactions Due to Toxoid Vaccines

Opportunities
  • Growth in the Healthcare Sector
  • Growing Target Patient Population

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Toxoid Vaccines Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Monovalent Tetanus Toxoid (TT)
  • Diphtheria
  • Tetanus
  • Pertussis (DTaP)
  • Diphtheria and Tetanus (DT)
By Forms
  • Quadrivalent
  • Pentavalent
  • Hexavalent

By End-users
  • Hospitals And Clinics
  • Government Organizations
  • Research
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Disease Caused by Microorganism such as Bacterial Infection
      • 3.2.2. Increased Number of Diagnostic Centres
      • 3.2.3. Increasing Healthcare Expenditure Across Emerging Markets
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Toxoid Vaccines, by Type, Forms, End-users and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Toxoid Vaccines (Value)
      • 5.2.1. Global Toxoid Vaccines by: Type (Value)
        • 5.2.1.1. Monovalent Tetanus Toxoid (TT)
        • 5.2.1.2. Diphtheria
        • 5.2.1.3. Tetanus
        • 5.2.1.4. Pertussis (DTaP)
        • 5.2.1.5. Diphtheria and Tetanus (DT)
      • 5.2.2. Global Toxoid Vaccines by: Forms (Value)
        • 5.2.2.1. Quadrivalent
        • 5.2.2.2. Pentavalent
        • 5.2.2.3. Hexavalent
      • 5.2.3. Global Toxoid Vaccines by: End-users (Value)
        • 5.2.3.1. Hospitals And Clinics
        • 5.2.3.2. Government Organizations
        • 5.2.3.3. Research
        • 5.2.3.4. Others
      • 5.2.4. Global Toxoid Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Toxoid Vaccines (Volume)
      • 5.3.1. Global Toxoid Vaccines by: Type (Volume)
        • 5.3.1.1. Monovalent Tetanus Toxoid (TT)
        • 5.3.1.2. Diphtheria
        • 5.3.1.3. Tetanus
        • 5.3.1.4. Pertussis (DTaP)
        • 5.3.1.5. Diphtheria and Tetanus (DT)
      • 5.3.2. Global Toxoid Vaccines by: Forms (Volume)
        • 5.3.2.1. Quadrivalent
        • 5.3.2.2. Pentavalent
        • 5.3.2.3. Hexavalent
      • 5.3.3. Global Toxoid Vaccines by: End-users (Volume)
        • 5.3.3.1. Hospitals And Clinics
        • 5.3.3.2. Government Organizations
        • 5.3.3.3. Research
        • 5.3.3.4. Others
      • 5.3.4. Global Toxoid Vaccines Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Toxoid Vaccines (Price)
      • 5.4.1. Global Toxoid Vaccines by: Type (Price)
  • 6. Toxoid Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi S.A. (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bharat Biotech International Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Shenzhen Kangtai Biological Products (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bausch Health Companies Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Emergent BioSolutions Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Toxoid Vaccines Sale, by Type, Forms, End-users and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Toxoid Vaccines (Value)
      • 7.2.1. Global Toxoid Vaccines by: Type (Value)
        • 7.2.1.1. Monovalent Tetanus Toxoid (TT)
        • 7.2.1.2. Diphtheria
        • 7.2.1.3. Tetanus
        • 7.2.1.4. Pertussis (DTaP)
        • 7.2.1.5. Diphtheria and Tetanus (DT)
      • 7.2.2. Global Toxoid Vaccines by: Forms (Value)
        • 7.2.2.1. Quadrivalent
        • 7.2.2.2. Pentavalent
        • 7.2.2.3. Hexavalent
      • 7.2.3. Global Toxoid Vaccines by: End-users (Value)
        • 7.2.3.1. Hospitals And Clinics
        • 7.2.3.2. Government Organizations
        • 7.2.3.3. Research
        • 7.2.3.4. Others
      • 7.2.4. Global Toxoid Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Toxoid Vaccines (Volume)
      • 7.3.1. Global Toxoid Vaccines by: Type (Volume)
        • 7.3.1.1. Monovalent Tetanus Toxoid (TT)
        • 7.3.1.2. Diphtheria
        • 7.3.1.3. Tetanus
        • 7.3.1.4. Pertussis (DTaP)
        • 7.3.1.5. Diphtheria and Tetanus (DT)
      • 7.3.2. Global Toxoid Vaccines by: Forms (Volume)
        • 7.3.2.1. Quadrivalent
        • 7.3.2.2. Pentavalent
        • 7.3.2.3. Hexavalent
      • 7.3.3. Global Toxoid Vaccines by: End-users (Volume)
        • 7.3.3.1. Hospitals And Clinics
        • 7.3.3.2. Government Organizations
        • 7.3.3.3. Research
        • 7.3.3.4. Others
      • 7.3.4. Global Toxoid Vaccines Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Toxoid Vaccines (Price)
      • 7.4.1. Global Toxoid Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Toxoid Vaccines: by Type(USD Million)
  • Table 2. Toxoid Vaccines Monovalent Tetanus Toxoid (TT) , by Region USD Million (2015-2020)
  • Table 3. Toxoid Vaccines Diphtheria , by Region USD Million (2015-2020)
  • Table 4. Toxoid Vaccines Tetanus , by Region USD Million (2015-2020)
  • Table 5. Toxoid Vaccines Pertussis (DTaP) , by Region USD Million (2015-2020)
  • Table 6. Toxoid Vaccines Diphtheria and Tetanus (DT) , by Region USD Million (2015-2020)
  • Table 7. Toxoid Vaccines: by Forms(USD Million)
  • Table 8. Toxoid Vaccines Quadrivalent , by Region USD Million (2015-2020)
  • Table 9. Toxoid Vaccines Pentavalent , by Region USD Million (2015-2020)
  • Table 10. Toxoid Vaccines Hexavalent , by Region USD Million (2015-2020)
  • Table 11. Toxoid Vaccines: by End-users(USD Million)
  • Table 12. Toxoid Vaccines Hospitals And Clinics , by Region USD Million (2015-2020)
  • Table 13. Toxoid Vaccines Government Organizations , by Region USD Million (2015-2020)
  • Table 14. Toxoid Vaccines Research , by Region USD Million (2015-2020)
  • Table 15. Toxoid Vaccines Others , by Region USD Million (2015-2020)
  • Table 16. South America Toxoid Vaccines, by Country USD Million (2015-2020)
  • Table 17. South America Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 18. South America Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 19. South America Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 20. Brazil Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 21. Brazil Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 22. Brazil Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 23. Argentina Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 24. Argentina Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 25. Argentina Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 26. Rest of South America Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 28. Rest of South America Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 29. Asia Pacific Toxoid Vaccines, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 32. Asia Pacific Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 33. China Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 34. China Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 35. China Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 36. Japan Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 37. Japan Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 38. Japan Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 39. India Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 40. India Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 41. India Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 42. South Korea Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 43. South Korea Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 44. South Korea Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 45. Taiwan Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 46. Taiwan Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 47. Taiwan Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 48. Australia Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 49. Australia Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 50. Australia Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 54. Europe Toxoid Vaccines, by Country USD Million (2015-2020)
  • Table 55. Europe Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 56. Europe Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 57. Europe Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 58. Germany Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 59. Germany Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 60. Germany Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 61. France Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 62. France Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 63. France Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 64. Italy Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 65. Italy Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 66. Italy Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 67. United Kingdom Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 69. United Kingdom Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 70. Netherlands Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 71. Netherlands Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 72. Netherlands Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 73. Rest of Europe Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 75. Rest of Europe Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 76. MEA Toxoid Vaccines, by Country USD Million (2015-2020)
  • Table 77. MEA Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 78. MEA Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 79. MEA Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 80. Middle East Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 81. Middle East Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 82. Middle East Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 83. Africa Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 84. Africa Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 85. Africa Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 86. North America Toxoid Vaccines, by Country USD Million (2015-2020)
  • Table 87. North America Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 88. North America Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 89. North America Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 90. United States Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 91. United States Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 92. United States Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 93. Canada Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 94. Canada Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 95. Canada Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 96. Mexico Toxoid Vaccines, by Type USD Million (2015-2020)
  • Table 97. Mexico Toxoid Vaccines, by Forms USD Million (2015-2020)
  • Table 98. Mexico Toxoid Vaccines, by End-users USD Million (2015-2020)
  • Table 99. Toxoid Vaccines Sales: by Type(K Units)
  • Table 100. Toxoid Vaccines Sales Monovalent Tetanus Toxoid (TT) , by Region K Units (2015-2020)
  • Table 101. Toxoid Vaccines Sales Diphtheria , by Region K Units (2015-2020)
  • Table 102. Toxoid Vaccines Sales Tetanus , by Region K Units (2015-2020)
  • Table 103. Toxoid Vaccines Sales Pertussis (DTaP) , by Region K Units (2015-2020)
  • Table 104. Toxoid Vaccines Sales Diphtheria and Tetanus (DT) , by Region K Units (2015-2020)
  • Table 105. Toxoid Vaccines Sales: by Forms(K Units)
  • Table 106. Toxoid Vaccines Sales Quadrivalent , by Region K Units (2015-2020)
  • Table 107. Toxoid Vaccines Sales Pentavalent , by Region K Units (2015-2020)
  • Table 108. Toxoid Vaccines Sales Hexavalent , by Region K Units (2015-2020)
  • Table 109. Toxoid Vaccines Sales: by End-users(K Units)
  • Table 110. Toxoid Vaccines Sales Hospitals And Clinics , by Region K Units (2015-2020)
  • Table 111. Toxoid Vaccines Sales Government Organizations , by Region K Units (2015-2020)
  • Table 112. Toxoid Vaccines Sales Research , by Region K Units (2015-2020)
  • Table 113. Toxoid Vaccines Sales Others , by Region K Units (2015-2020)
  • Table 114. South America Toxoid Vaccines Sales, by Country K Units (2015-2020)
  • Table 115. South America Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 116. South America Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 117. South America Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 118. Brazil Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 119. Brazil Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 120. Brazil Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 121. Argentina Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 122. Argentina Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 123. Argentina Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 124. Rest of South America Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 125. Rest of South America Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 126. Rest of South America Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 127. Asia Pacific Toxoid Vaccines Sales, by Country K Units (2015-2020)
  • Table 128. Asia Pacific Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 129. Asia Pacific Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 130. Asia Pacific Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 131. China Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 132. China Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 133. China Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 134. Japan Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 135. Japan Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 136. Japan Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 137. India Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 138. India Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 139. India Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 140. South Korea Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 141. South Korea Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 142. South Korea Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 143. Taiwan Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 144. Taiwan Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 145. Taiwan Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 146. Australia Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 147. Australia Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 148. Australia Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 149. Rest of Asia-Pacific Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 150. Rest of Asia-Pacific Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 151. Rest of Asia-Pacific Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 152. Europe Toxoid Vaccines Sales, by Country K Units (2015-2020)
  • Table 153. Europe Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 154. Europe Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 155. Europe Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 156. Germany Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 157. Germany Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 158. Germany Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 159. France Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 160. France Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 161. France Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 162. Italy Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 163. Italy Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 164. Italy Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 165. United Kingdom Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 166. United Kingdom Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 167. United Kingdom Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 168. Netherlands Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 169. Netherlands Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 170. Netherlands Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 171. Rest of Europe Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 172. Rest of Europe Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 173. Rest of Europe Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 174. MEA Toxoid Vaccines Sales, by Country K Units (2015-2020)
  • Table 175. MEA Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 176. MEA Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 177. MEA Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 178. Middle East Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 179. Middle East Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 180. Middle East Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 181. Africa Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 182. Africa Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 183. Africa Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 184. North America Toxoid Vaccines Sales, by Country K Units (2015-2020)
  • Table 185. North America Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 186. North America Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 187. North America Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 188. United States Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 189. United States Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 190. United States Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 191. Canada Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 192. Canada Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 193. Canada Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 194. Mexico Toxoid Vaccines Sales, by Type K Units (2015-2020)
  • Table 195. Mexico Toxoid Vaccines Sales, by Forms K Units (2015-2020)
  • Table 196. Mexico Toxoid Vaccines Sales, by End-users K Units (2015-2020)
  • Table 197. Toxoid Vaccines: by Type(USD/Units)
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Toxoid Vaccines: by Type(USD Million)
  • Table 208. Toxoid Vaccines Monovalent Tetanus Toxoid (TT) , by Region USD Million (2021-2026)
  • Table 209. Toxoid Vaccines Diphtheria , by Region USD Million (2021-2026)
  • Table 210. Toxoid Vaccines Tetanus , by Region USD Million (2021-2026)
  • Table 211. Toxoid Vaccines Pertussis (DTaP) , by Region USD Million (2021-2026)
  • Table 212. Toxoid Vaccines Diphtheria and Tetanus (DT) , by Region USD Million (2021-2026)
  • Table 213. Toxoid Vaccines: by Forms(USD Million)
  • Table 214. Toxoid Vaccines Quadrivalent , by Region USD Million (2021-2026)
  • Table 215. Toxoid Vaccines Pentavalent , by Region USD Million (2021-2026)
  • Table 216. Toxoid Vaccines Hexavalent , by Region USD Million (2021-2026)
  • Table 217. Toxoid Vaccines: by End-users(USD Million)
  • Table 218. Toxoid Vaccines Hospitals And Clinics , by Region USD Million (2021-2026)
  • Table 219. Toxoid Vaccines Government Organizations , by Region USD Million (2021-2026)
  • Table 220. Toxoid Vaccines Research , by Region USD Million (2021-2026)
  • Table 221. Toxoid Vaccines Others , by Region USD Million (2021-2026)
  • Table 222. South America Toxoid Vaccines, by Country USD Million (2021-2026)
  • Table 223. South America Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 224. South America Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 225. South America Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 226. Brazil Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 227. Brazil Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 228. Brazil Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 229. Argentina Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 230. Argentina Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 231. Argentina Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 232. Rest of South America Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 233. Rest of South America Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 234. Rest of South America Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 235. Asia Pacific Toxoid Vaccines, by Country USD Million (2021-2026)
  • Table 236. Asia Pacific Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 237. Asia Pacific Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 238. Asia Pacific Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 239. China Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 240. China Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 241. China Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 242. Japan Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 243. Japan Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 244. Japan Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 245. India Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 246. India Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 247. India Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 248. South Korea Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 249. South Korea Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 250. South Korea Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 251. Taiwan Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 252. Taiwan Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 253. Taiwan Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 254. Australia Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 255. Australia Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 256. Australia Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 257. Rest of Asia-Pacific Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 258. Rest of Asia-Pacific Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 259. Rest of Asia-Pacific Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 260. Europe Toxoid Vaccines, by Country USD Million (2021-2026)
  • Table 261. Europe Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 262. Europe Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 263. Europe Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 264. Germany Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 265. Germany Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 266. Germany Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 267. France Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 268. France Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 269. France Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 270. Italy Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 271. Italy Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 272. Italy Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 273. United Kingdom Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 274. United Kingdom Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 275. United Kingdom Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 276. Netherlands Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 277. Netherlands Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 278. Netherlands Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 279. Rest of Europe Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 280. Rest of Europe Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 281. Rest of Europe Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 282. MEA Toxoid Vaccines, by Country USD Million (2021-2026)
  • Table 283. MEA Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 284. MEA Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 285. MEA Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 286. Middle East Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 287. Middle East Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 288. Middle East Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 289. Africa Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 290. Africa Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 291. Africa Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 292. North America Toxoid Vaccines, by Country USD Million (2021-2026)
  • Table 293. North America Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 294. North America Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 295. North America Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 296. United States Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 297. United States Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 298. United States Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 299. Canada Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 300. Canada Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 301. Canada Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 302. Mexico Toxoid Vaccines, by Type USD Million (2021-2026)
  • Table 303. Mexico Toxoid Vaccines, by Forms USD Million (2021-2026)
  • Table 304. Mexico Toxoid Vaccines, by End-users USD Million (2021-2026)
  • Table 305. Toxoid Vaccines Sales: by Type(K Units)
  • Table 306. Toxoid Vaccines Sales Monovalent Tetanus Toxoid (TT) , by Region K Units (2021-2026)
  • Table 307. Toxoid Vaccines Sales Diphtheria , by Region K Units (2021-2026)
  • Table 308. Toxoid Vaccines Sales Tetanus , by Region K Units (2021-2026)
  • Table 309. Toxoid Vaccines Sales Pertussis (DTaP) , by Region K Units (2021-2026)
  • Table 310. Toxoid Vaccines Sales Diphtheria and Tetanus (DT) , by Region K Units (2021-2026)
  • Table 311. Toxoid Vaccines Sales: by Forms(K Units)
  • Table 312. Toxoid Vaccines Sales Quadrivalent , by Region K Units (2021-2026)
  • Table 313. Toxoid Vaccines Sales Pentavalent , by Region K Units (2021-2026)
  • Table 314. Toxoid Vaccines Sales Hexavalent , by Region K Units (2021-2026)
  • Table 315. Toxoid Vaccines Sales: by End-users(K Units)
  • Table 316. Toxoid Vaccines Sales Hospitals And Clinics , by Region K Units (2021-2026)
  • Table 317. Toxoid Vaccines Sales Government Organizations , by Region K Units (2021-2026)
  • Table 318. Toxoid Vaccines Sales Research , by Region K Units (2021-2026)
  • Table 319. Toxoid Vaccines Sales Others , by Region K Units (2021-2026)
  • Table 320. South America Toxoid Vaccines Sales, by Country K Units (2021-2026)
  • Table 321. South America Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 322. South America Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 323. South America Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 324. Brazil Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 325. Brazil Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 326. Brazil Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 327. Argentina Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 328. Argentina Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 329. Argentina Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 330. Rest of South America Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 331. Rest of South America Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 332. Rest of South America Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 333. Asia Pacific Toxoid Vaccines Sales, by Country K Units (2021-2026)
  • Table 334. Asia Pacific Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 335. Asia Pacific Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 336. Asia Pacific Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 337. China Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 338. China Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 339. China Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 340. Japan Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 341. Japan Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 342. Japan Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 343. India Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 344. India Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 345. India Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 346. South Korea Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 347. South Korea Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 348. South Korea Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 349. Taiwan Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 350. Taiwan Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 351. Taiwan Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 352. Australia Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 353. Australia Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 354. Australia Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 355. Rest of Asia-Pacific Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 356. Rest of Asia-Pacific Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 357. Rest of Asia-Pacific Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 358. Europe Toxoid Vaccines Sales, by Country K Units (2021-2026)
  • Table 359. Europe Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 360. Europe Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 361. Europe Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 362. Germany Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 363. Germany Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 364. Germany Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 365. France Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 366. France Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 367. France Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 368. Italy Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 369. Italy Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 370. Italy Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 371. United Kingdom Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 372. United Kingdom Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 373. United Kingdom Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 374. Netherlands Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 375. Netherlands Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 376. Netherlands Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 377. Rest of Europe Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 378. Rest of Europe Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 379. Rest of Europe Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 380. MEA Toxoid Vaccines Sales, by Country K Units (2021-2026)
  • Table 381. MEA Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 382. MEA Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 383. MEA Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 384. Middle East Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 385. Middle East Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 386. Middle East Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 387. Africa Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 388. Africa Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 389. Africa Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 390. North America Toxoid Vaccines Sales, by Country K Units (2021-2026)
  • Table 391. North America Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 392. North America Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 393. North America Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 394. United States Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 395. United States Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 396. United States Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 397. Canada Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 398. Canada Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 399. Canada Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 400. Mexico Toxoid Vaccines Sales, by Type K Units (2021-2026)
  • Table 401. Mexico Toxoid Vaccines Sales, by Forms K Units (2021-2026)
  • Table 402. Mexico Toxoid Vaccines Sales, by End-users K Units (2021-2026)
  • Table 403. Toxoid Vaccines: by Type(USD/Units)
  • Table 404. Research Programs/Design for This Report
  • Table 405. Key Data Information from Secondary Sources
  • Table 406. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Toxoid Vaccines: by Type USD Million (2015-2020)
  • Figure 5. Global Toxoid Vaccines: by Forms USD Million (2015-2020)
  • Figure 6. Global Toxoid Vaccines: by End-users USD Million (2015-2020)
  • Figure 7. South America Toxoid Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Toxoid Vaccines Share (%), by Country
  • Figure 9. Europe Toxoid Vaccines Share (%), by Country
  • Figure 10. MEA Toxoid Vaccines Share (%), by Country
  • Figure 11. North America Toxoid Vaccines Share (%), by Country
  • Figure 12. Global Toxoid Vaccines: by Type K Units (2015-2020)
  • Figure 13. Global Toxoid Vaccines: by Forms K Units (2015-2020)
  • Figure 14. Global Toxoid Vaccines: by End-users K Units (2015-2020)
  • Figure 15. South America Toxoid Vaccines Share (%), by Country
  • Figure 16. Asia Pacific Toxoid Vaccines Share (%), by Country
  • Figure 17. Europe Toxoid Vaccines Share (%), by Country
  • Figure 18. MEA Toxoid Vaccines Share (%), by Country
  • Figure 19. North America Toxoid Vaccines Share (%), by Country
  • Figure 20. Global Toxoid Vaccines: by Type USD/Units (2015-2020)
  • Figure 21. Global Toxoid Vaccines share by Players 2020 (%)
  • Figure 22. Global Toxoid Vaccines share by Players (Top 3) 2020(%)
  • Figure 23. Global Toxoid Vaccines share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 33. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Bharat Biotech International Limited (India) Revenue, Net Income and Gross profit
  • Figure 36. Bharat Biotech International Limited (India) Revenue: by Geography 2020
  • Figure 37. Shenzhen Kangtai Biological Products (China) Revenue, Net Income and Gross profit
  • Figure 38. Shenzhen Kangtai Biological Products (China) Revenue: by Geography 2020
  • Figure 39. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 40. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2020
  • Figure 41. Emergent BioSolutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Emergent BioSolutions Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Global Toxoid Vaccines: by Type USD Million (2021-2026)
  • Figure 44. Global Toxoid Vaccines: by Forms USD Million (2021-2026)
  • Figure 45. Global Toxoid Vaccines: by End-users USD Million (2021-2026)
  • Figure 46. South America Toxoid Vaccines Share (%), by Country
  • Figure 47. Asia Pacific Toxoid Vaccines Share (%), by Country
  • Figure 48. Europe Toxoid Vaccines Share (%), by Country
  • Figure 49. MEA Toxoid Vaccines Share (%), by Country
  • Figure 50. North America Toxoid Vaccines Share (%), by Country
  • Figure 51. Global Toxoid Vaccines: by Type K Units (2021-2026)
  • Figure 52. Global Toxoid Vaccines: by Forms K Units (2021-2026)
  • Figure 53. Global Toxoid Vaccines: by End-users K Units (2021-2026)
  • Figure 54. South America Toxoid Vaccines Share (%), by Country
  • Figure 55. Asia Pacific Toxoid Vaccines Share (%), by Country
  • Figure 56. Europe Toxoid Vaccines Share (%), by Country
  • Figure 57. MEA Toxoid Vaccines Share (%), by Country
  • Figure 58. North America Toxoid Vaccines Share (%), by Country
  • Figure 59. Global Toxoid Vaccines: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Pfizer Inc. (United States)
  • Sanofi S.A. (France)
  • AstraZeneca plc (United Kingdom)
  • Bharat Biotech International Limited (India)
  • Shenzhen Kangtai Biological Products (China)
  • Bausch Health Companies Inc. (Canada)
  • Emergent BioSolutions Inc. (United States)
Additional players considered in the study are as follows:
Astellas Pharma Inc. (Japan) , Panacea Biotec (India)
Select User Access Type

Key Highlights of Report


Oct 2021 249 Pages 91 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Toxoid Vaccines Quantitative research analysis
Global Toxoid Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Disease Caused by Microorganism such as Bacterial Infection " is seen as one of major growth factors of Toxoid Vaccines Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Toxoid Vaccines Market in coming years.

Know More About Global Toxoid Vaccines Report?

Have a Query? Click Here

Other Related Reports

Ophthalmoplegia Comprehensive Study by Type (External Ophthalmoplegia, Internuclear Ophthalmoplegia), Application (Telemedicine Platforms, Assistive Technology Application, Low Vision Aid Apps), End ...
$ 3500
Brain Tumor Diagnosis and Treatments Comprehensive Study by Type (Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors), Secondary Brain Tumor), Applic...
$ 3750
Tuberculosis Treatment Drugs Comprehensive Study by Type (Active TB, Latent TB), Application (Hospital, Clinic, Durgstore), Drugs (First Line anti-TB Drugs, Second Line anti- TB Drugs) Players and Re...
$ 3500
Acute Disease Comprehensive Study by Type (Acute minor illness (self-limiting), Acute major illness (self-limiting or requiring treatment), Acute presentation of existing major illness (acute exacerb...
$ 3650
Bone Growth Stimulator Comprehensive Study by Application (Spinal Fusion, Delay Union & Non-union Bone Fracture, Oral-maxillofacial, Other Applications), Stimulators (Internal Bone Growth Stimulators...
$ 3750
Cancer Therapeutics Comprehensive Study by Application (Blood cancer, Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Other), Drug Selling (Revlimid, Avastin, Herceptin, Rituxan, Opdi...
$ 3800